Drug Combination Details
| General Information of the Combination (ID: C01222) | |||||
|---|---|---|---|---|---|
| Name | Pterostilbene NP Info | + | Vorinostat Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | HIF-1A | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MTA1 | Molecule Info | |||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
| In-vivo Model | Female C57BL/6J mouse homozygous with "floxed" allele of Pten gene were used in this study. | |||||
| Experimental
Result(s) |
Pterostilbene sensitized tumor cells to SAHA treatment resulting in inhibiting tumor growth and additional decline of tumor progression. These effects were dependent on the reduction of MTA1-associated proangiogenic factors HIF-1Alpha, VEGF, and IL-1Beta leading to decreased angiogenesis. | |||||
